Just_a_Guy,
Apologies, I didn't quite answer your question fully.
The difference between my net debt forecast and the reported outcome is due to two major variances:
1. Working capital, the company ending the period with some $8m less of it than I had forecast (essentially, a 40bp difference in Working Cap-to-Sales terms). So, 2H2017 OCF was $116m compared to my $103m forecast.
2. As you rightly deduced, the other major variance was that my capex estimate was for $70m in the second half (it was $49m in 1H2017), while the actual result of $47m was actually less than 1H2017. So there is a further $23m of net debt variance explained, I clearly gauged the timing of the capital expenditure on the new factory incorrectly. But it is really a mere timing issue, because for the current half, I had only $30m of capex in my model, and I now think it will be about $50m. So, really, it's just a 6 month lag of some $20m of capex... largely "forecasting noise".
The significant aspect of what is happening with this company here is testimony to its prolific cash flow generation.
For here is a business that is undertaking a once-a-generational total renewal of its manufacturing base, while continuing to pay out ~75% of its profits to the owners of the business, and yet over the period this is all happening, Net-Debt-to-EBITDA will still have been reduced:
Net Debt-t0-EBITDA (times):
SH2014: 1.7
MH2015: 2.0
SH2015: 1.5
MH2016: 1.7
SH2016: 1.5
MH2017: 1.6
SH2017: 1.5
MH2018: 1.5 (E)
SH2018: 1.4 (E)
Not many companies that can deliver that sort of outcome.
- Forums
- ASX - By Stock
- DLX
- Full-Year Result Expectations
Full-Year Result Expectations, page-12
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DLX (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online